Abstract:Purpose We investigated plasma angiotensin-converting enzyme 2 (ACE2) concentration in a population sample and the ACE2 expression quantitated with the diaminobenzidine mean intensity in the lung tissue in patients who underwent lung surgery. Materials and methods The study participants were recruited from a residential area in the suburb of Shanghai for the plasma ACE2 concentration study (n = 503) and the lung tissue samples were randomly selected from the storage in Ruijin Hospital (80 men and 78 age-matched women). Results In analyses adjusted for covariables, men had a significantly higher plasma ACE2 concentration (1.21 vs. 0.98 ng/mL, p = 0.027) and the mean intensity of ACE2 in the lung tissue (55.1 vs. 53.9 a.u., p = 0.037) than women. With age increasing, plasma ACE2 concentration decreased (p = 0.001), while the mean intensity of ACE2 in the lung tissue tended to increase (p = 0.087). Plasma ACE2 concentration was higher in hypertension than normotension, especially treated hypertension (1.23 vs. 0.98 ng/mL, p = 0.029 vs. normotension), with no significant difference between users of RAS inhibitors and other classes of antihypertensive drugs (p = 0.64). There was no significance of the mean intensity of ACE2 in the lung tissue between patients taking and those not taking RAS inhibitors (p = 0.14). Neither plasma ACE2 concentration nor the mean intensity of ACE2 in the lung tissue differed between normoglycemia and diabetes (p >= 0.20). Conclusion ACE2 in the plasma and lung tissue showed divergent changes according to several major characteristics of patients. Plain language summary What is the context? center dot The primary physiological function of ACE2 is the degradation of angiotensin I and II to angiotensin 1-9 and 1-7, respectively. center dot ACE2 was found to behave as a mediator of the severe acute respiratory syndrome coronavirus (SARS) infection. center dot There is little research on ACE2 in humans, especially in the lung tissue. center dot In the present report, we investigated plasma ACE2 concentration and the ACE2 expression quantitated with the diaminobenzidine mean intensity in the lung tissue respectively in two study populations. What is new? center dot Our study investigated both circulating and tissue ACE2 in human subjects. The main findings were: center dot In men as well as women, plasma ACE2 concentration was higher in younger than older participants, whereas the mean intensity of ACE2 in the lung tissue increase with age increasing. center dot Compared with normotension, hypertensive patients had higher plasma ACE2 concentration but similar mean intensity of ACE2 in the lung tissue. center dot Neither plasma ACE2 concentration nor lung tissue ACE2 expression significantly differed between users of RAS inhibitors and other classes of antihypertensive drugs. What is the impact? center dot ACE2 in the plasma and lung tissue showed divergent changes according to several major characteristics, such as sex, age, and treated and untreated hypertension. center dot A major implication is that plasma ACE2 concentration might not be an appropriate surrogate for the ACE2 expression in the lung tissue, and hence not a good predictor of SARS-COV-2 infection or fatality.

A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9

Rediscovering ACE: Novel Insights into the Many Roles of the Angiotensin-Converting Enzyme

Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Characterizations of angiotensin-converting enzyme-2 (ACE2) peptidase activity

Angiotensin-converting enzyme: a well-known stranger. Part I

[Effects of Angiotensin Converting Enzyme Inhibitor on the Expression of Angiotensin Converting Enzyme 2 in Atrium of Patients with Atrial Fibrillation].

[Cloning, expression and sequence analysis and tissue distribution of angiotensin-converting enzyme 2 (ACE2) gene in adult mice].

Angiotensin Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis and Diastolic Dysfunction

Prevention of Angiotensin II-induced Hypertension and Cardiac Remodeling by Recombinant Human Angiotensin-Converting Enzyme 2 in Mice

Advances in Research into Angiotensin-Converting Enzyme 2

Droplet microfluidic screening to engineer angiotensin-converting enzyme 2 (ACE2) catalytic activity

Progress of Studies on Angiotensin-Converting Enzyme 2 in Lung Disease

ACE2 Shedding and the Role in COVID-19

Angiotensin-converting Enzyme 2 Attenuates Atherosclerotic Lesions by Targeting Vascular Cells

Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets

The 2023 Lewis K. Dahl Memorial Lecture: Angiotensin-Converting Enzyme 2 Posttranslational Modifications—Implications for Hypertension and SARS-CoV-2 Infection

Angiotensin-converting Enzyme 2 (ACE2): SARS-CoV-2 Receptor and RAS Modulator

ACE2 is a negative regulator of profilin-1 expression and collagen production in cultured adult murine cardiomyocytes

B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction

Angiotensin-converting Enzyme 2 in Human Plasma and Lung Tissue.